Frontage has successfully filed an Investigational New Drug (IND) on behalf of Zhejiang Hisun Pharmaceutical Co. to initiate an early phase clinical study for HS-25, a cholesterol-lowering compound to treat hypercholesterolemia and nephrotic hyperlipidemia.
 
As the U.S. regulatory agent for Hisun, Frontage supported the HS-25 IND filing with drug development and regulatory consulting services, including CMC and pharmaceutical toxicology, plus the clinical development plan and protocols. Frontage also communicated with the FDA from the pre-IND meeting through the IND filing and post-IND discussions. Frontage will conduct the Phase I trial and other clinical pharmacology studies for HS-25 at its U.S. clinical center.